Pharmanutra Full Year 2024 Earnings: EPS Misses Expectations

Pharmanutra (BIT:PHN) Full Year 2024 Results

Key Financial Results

• Revenue: €116.1m (up 15% from FY 2023).
• Net income: €16.6m (up 29% from FY 2023).
• Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: €1.73 (up from €1.33 in FY 2023).

The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pharmanutra EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.1%.

The primary driver behind last 12 months revenue was the Italy segment contributing a total revenue of €70.2m (60% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to €18.5m (43% of total expenses). Explore how PHN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.

Performance of the market in Italy.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Pharmanutra's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.